ReviewGeneral psychiatry2025
Decline in activities of daily living in the rarer dementias.
Review in General psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rarer dementias are associated with atypical symptoms and younger onset, which result in a higher burden of care. We provide a review of the global literature on longitudinal decline in activities of daily living (ADLs) in dementias that account for less than 10% of dementia diagnoses. Published studies were identified through searches conducted in Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica Database (Embase), Excerpta Medica Care (Emcare), PsycINFO, and Cumulative Index in Nursing and Allied Health Literature (CINAHL). The search criteria included terms related to 'rarer dementias', 'activities of daily living' and 'longitudinal or cross-sectional studies' following a predefined protocol registered. Studies were screened, and those that met the criteria were citation searched. Quality assessments were performed, and relevant data were extracted. 20 articles were selected, of which 19 focused on dementias within the frontotemporal dementia/primary progressive aphasia spectrum, while one addressed posterior cortical atrophy. Four studies were cross-sectional and 16 studies were longitudinal, with a median duration of 2.2 years. The Disability Assessment for Dementia was used to measure decline in 8 of the 20 studies. The varied sequences of ADL decline reported in the literature reflect variation in diagnostic specificity between studies and within-syndrome heterogeneity. Most studies used Alzheimer's disease staging scales to measure decline, which cannot capture variant-specific symptoms. To enhance care provision in dementia, ADL scales could be deployed postdiagnosis to aid treatment and planning. This necessitates staging scales that are variant-specific and span the disease course from diagnosis to end of life. PROSPERO registration number: CRD42021283302.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.